Obesity News and Research

Latest Obesity News and Research

Exploring the relationship between testosterone and men's health

The review article titled"Testosterone and men's health: An in-depth exploration of their relationship", was published on February 18, 2025 in UroPrecision.

2 Apr 2025

Vegetarian diets may hinder healthy aging—unless diet quality is high

Older Chinese adults who followed vegetarian diets were less likely to reach age 80 in good health. However, this disadvantage disappeared for those consuming high-quality plant-based diets.

2 Apr 2025

High-fat diet linked to increased breast cancer metastasis risk

Obesity is associated with an increased risk of developing breast cancer, and a greater probability for the cancer to spread to other organs – metastasize –. But the causes of this association are still not well understood.

2 Apr 2025

Football proven to prevent and treat lifestyle diseases

Danish researchers, in collaboration with the Danish Football Association, have released a White Paper that describes football as an effective recipe in the prevention and treatment of lifestyle-related diseases.

2 Apr 2025

New study explores link between gut microbiome and autism spectrum disorder

Researchers evaluate the relationship between the gut microbiome and autism spectrum disorder.

2 Apr 2025

Rural communities face higher rates of heart disease and risk factors

A research team funded by the National Institutes of Health (NIH) uncovered higher rates of heart disease and worse heart health affecting adults living in rural communities compared to urban areas and the factors that likely drive these differences.

1 Apr 2025

Rare sugars curb appetite and mimic diabetes drugs in mice

Rare sugars like D-allulose, D-tagatose, and D-sorbose significantly boosted GLP-1 secretion and suppressed food intake in mice. D-allose also reduced food intake through a unique, GLP-1-independent pathway.

1 Apr 2025

Pregnancy may provide some protection against Long COVID

Pregnancy may offer some protection from developing Long COVID, found a new study led by Weill Cornell Medicine, University of Rochester Medical Center, University of Utah Health and Louisiana Public Health Institute.

1 Apr 2025

Gastric bypass proven most effective for severe obesity in landmark study

Gastric bypass is the most clinically and cost effective form of interventional surgery for people living with severe obesity, reveals landmark research funded and supported by the National Institute for Health and Care Research (NIHR).

1 Apr 2025

Study links linoleic acid to triple-negative breast cancer growth

Linoleic acid, an omega-6 fatty acid found in seed oils such as soybean and safflower oil, and animal products including pork and eggs, specifically enhances the growth of the hard-to-treat "triple negative" breast cancer subtype, according to a preclinical study led by Weill Cornell Medicine investigators.

1 Apr 2025

Do lifetime body weight patterns affect kidney cancer risk?

Excess weight in mid-life is a known risk factor for kidney cancer, but new research indicates that weight patterns throughout life may also affect an individual’s likelihood of developing this malignancy.

1 Apr 2025

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).

1 Apr 2025

Study: Mental health providers often miss bulimia diagnosis

When presented with a vignette describing the behaviors and characteristics of a patient with disordered eating, only a quarter of mental health providers who participated in a new study were able to correctly diagnose bulimia nervosa.

1 Apr 2025

Tirzepatide improves kidney, cardiovascular function in patients with obesity and HFpEF

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, according to featured clinical research presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in JACC.

31 Mar 2025

What blueberries do and don’t do for your microbiome and heart

Regular blueberry consumption for 12 weeks enriched Coriobacteriales incertae sedis in the gut microbiota of older overweight adults. However, this microbial shift was not linked to significant improvements in cardiometabolic biomarkers.

31 Mar 2025

Five lifestyle changes by 50 can add a decade to your life, global study finds

Study estimates the global lifetime risk and benefits of modifying cardiovascular risk factors like hypertension, smoking, and obesity by age 50, showing significant improvements in both life expectancy and quality of life. It highlights the importance of early intervention and midlife changes in preventing cardiovascular disease and mortality.

31 Mar 2025

Hedonic eating fades with obesity—but neurotensin helps bring it back

Chronic high-fat diets blunt the brain’s pleasure response to rich foods by impairing NAcLat→VTA signaling in mice. Neurotensin dysfunction underlies this effect, but restoring its signaling revives hedonic feeding and reduces obesity symptoms.

30 Mar 2025

Why sucralose could make you hungrier instead of helping you lose weight

Sucralose increases hypothalamic activity linked to hunger more than sugar or water, especially in women and people with obesity.

30 Mar 2025

WARRIOR trial finds no impact of intensive therapy on heart events in women

An intensive three-drug regimen of heart medications did not significantly impact the rate of serious cardiovascular events at five years in women who experienced signs and symptoms of ischemia, or insufficient blood flow to the heart muscle, but had no blockages in their heart's arteries, according to research presented at the American College of Cardiology's Annual Scientific Session.

29 Mar 2025

Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetes

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first-of-its kind trial to evaluate the use of a GLP-1 agonist to manage PAD.

29 Mar 2025